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Abstract
Upregulation of group IIA phospholipase A2 (sPLA2-IIA) correlates with prostate tumor progression suggesting
prooncogenic properties of this protein. Here, we report data on expression of three different sPLA2 isozymes
(groups IIA, V, and X) in normal (PrEC) and malignant (DU-145, PC-3, and LNCaP) human prostate cell lines. All
studied cell lines constitutively expressed sPLA2-X, whereas sPLA2-V transcripts were identified only in malignant
cells. In contrast, no expression of sPLA2-IIA was found in PrEC and DU-145 cells, but it was constitutively expressed
by IFN-γ in LNCaP and PC-3 cells. Expression of sPLA2-IIA is upregulated in PC-3 and in PrEC cell in a signal trans-
ducer and activator of transcription-1–dependent manner, but not in LNCaP cell. Additional signaling pathways reg-
ulating sPLA2-IIA expression include cAMP/protein kinase A, p38 mitogen-activated protein kinase, protein kinase C,
Rho-kinase, and mitogen-activated/extracellular response protein kinase / extracellular signal–regulated kinase. No
deletions were revealed in the sPLA2-IIA gene from DU-145 cells lacking the expression of sPLA2-IIA. Reexpression
of sPLA2-IIA was induced by 5-aza-2′-deoxycytidine demonstrating that DNA methylation is implicated in the regula-
tion of sPLA2-II. Together, these data suggest that sPLA2-IIA and sPLA2-V, but not sPLA2-X, are differentially ex-
pressed in normal and malignant prostate cells under the control of proinflammatory cytokines; epigenetic
mechanisms appear involved in the regulation of sPLA2-IIA expression, at least in DU-145 cells.
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Introduction
Secretory phospholipases A2 (sPLA2, phosphatide sn-2-acylhydrolases;
EC 3.1.1.4) belong to a growing and structurally heterogenous super-
family of phospholipases that play a critical role in a number of relevant
physiological processes including defense mechanisms, production of
bioactive lipids, and cell signaling [1–3]. At present, 10 different human
sPLA2 isozymes are known. Among these, the group IIA isozyme,
sPLA2-IIA, is the best established to contribute to the pathogenesis
of inflammatory diseases such as sepsis and septic shock, rheumatoid
arthritis, and atherosclerosis [1–3]. Other studies suggest that sPLA2-
IIA is also important for the genesis of different cancers [4–11]. For
example, increased expression of sPLA2-IIA correlates with tumor
grade in human colon cancer and Barrett’s adenocarcinoma [12,13].
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Furthermore, increased levels of this enzyme have been found in the
extracellular microenvironment of prostate cancer tissues and cell lines
[4–6] correlating with poor survival [7] and high aggressiveness [8].
The role of sPLA2-IIA in tumorigenesis, however, remains unre-
solved. A protective function of sPLA2-IIA has been suggested from
data in Min mice, in which mutations of the adenomatous polyposis
coli gene lead to the development of multiple adenomas throughout
their small and large intestines [14]. However, this function could
not be proven in humans where sPLA2-IIA gene mutations do not
appear to play a major role in the development of colorectal cancers
[15,16]. Otherwise, in human pancreatic cancer cells and gastric ade-
nocarcinoma, the expression of sPLA2-IIA was associated with pro-
longed survival and less frequent metastasis [14,17,18]. In contrast,
prooncogenic properties of sPLA2-IIA upregulation have been sug-
gested from studies on different tumor cell lines and xenograft tumor
models [6,19,20].
The expression of sPLA2-IIA is regulated through a number of
growth peptides, cytokines, and transcription factors in a cell-type–
specific manner [1–3,21]. However, the role of proinflammatory cy-
tokines and related signaling pathways in the regulation of sPLA2-IIA
in prostate cancer cell lines remains to be determined. This ques-
tion has special interest because of the well-known relationship be-
tween progression of cancers and levels of proinflammatory cytokines
such as tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and
interleukin-6 (IL-6) [22–26]. It was suggested that transcription fac-
tors such as nuclear factor-kappa B (NF-κB) and members of the
signal transducer and activator of transcription (STAT) family play
pivotal roles in transmitting proinflammatory cytokine signals during
tumor development [27]. These transcription factors are necessary at
the same time for sPLA2-IIA promoter activity [3].
The potential contribution of proinflammatory cytokines to the
expression of sPLA2 in prostate cancer cells provided the premise
for the present study. To this end, we analyzed the expression of three
sPLA2 isozymes in malignant prostate cell lines and compared the
expression pattern with that found in normal prostate epithelial cells.
Materials and Methods
Materials
Recombinant human interleukin-1β (IL-1β), IL-6, TNF-α, and
IFN-γ were purchased from Roche Diagnostics Applied Science
(Mannheim, Germany). 2′-Amino-3′-methoxyflavone (PD98059),
Janus kinase ( JAK) inhibitor-I, 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-
5-(4-pyridyl)1H-imidazole (SB-202190), phorbol-12-myristate 13-acetate
(PMA), and (s)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]-
homopiperazine, 2HCl (H-1152) were obtained from Calbiochem
(San Diego, CA). Forskolin, N-acetyl-L-cysteine, 5-aza-2′-deoxycytidine
(5-aza-dC), mithramycin A, and caffeic acid phenethyl ester (CAPE) were
purchased from Sigma-Aldrich (Deisenhofen, Germany). Phorbol-12-
myristate 13-acetate, PD98059, forskolin, SB-202190, mithramycin A,
JAK inhibitor-I, and CAPE were dissolved in dimethyl sulfoxide
(DMSO). The final concentrations of solvents were 0.3% or less. Con-
trols using DMSO alone were run in all cases.
Cell Culture and Incubation
Normal human prostate epithelial cells (PrEC; Cambrex Bio Sci-
ence, Walkersville, MD) were maintained up to a maximum of six
passages in prostate epithelial growth medium supplemented with
bovine pituitary extract, epidermal growth factor, insulin, transferrin,
hydrocortisone, retinoic acid, epinephrine, triiodothyronine, and
gentamicin–amphotericin solution on dishes coated with collagen
type I (BioCoat; BD Falcon, Heidelberg, Germany). Every 2 to 3 days,
the medium was changed, and before reaching confluence, the cells
were passaged using trypsin/ethylenediaminetetraacetic acid.
Human prostatic malignant cell lines (PC-3, DU-145, and LNCaP
cells) were purchased from the German Collection of Microorganisms
and Cell Cultures (Berlin, Germany). They were cultured in a stan-
dard cell culture medium RPMI 1640 supplemented with 10%
heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml
penicillin, and 100 μg/ml streptomycin at 37°C in a humidified atmo-
sphere of 5% CO2.
For 5-aza-dC treatment, DU-145 cells were cultured in RPMI
1640 cell medium containing 10% FCS and 5-aza-dC added to the
final concentration of 1 to 10 μM from a freshly prepared 10-mM
stock solution. After 2 to 4 days, the cells were harvested and analyzed
for sPLA2-IIA protein and mRNA levels [28].
RNA Extraction and Reverse Transcription–Polymerase Chain
Reaction Analysis
RNA was isolated after lysing cells in TRI Reagent (Sigma-Aldrich)
according to the manufacturer’s instructions. Isolated RNA was con-
verted to cDNA using the GeneAmp RNA-PCR Kit (PerkinElmer
LAS GmbH, Jügesheim, Germany). A portion of the reverse transcrip-
tion (RT) reaction products was then amplified for the identification
of sPLA2-IIA, -V, -X, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH ) as a housekeeping gene using polymerase chain reaction
(PCR). The applied primer pairs were 5′-GTG ATC ATG ATC
TTT GGC CTA CTG CA-3′ and 5′-TCT CCC TCG TGG
GGA GCA ACG ACT-3′ for sPLA2-IIA, giving PCR products with
a length of 411 bp, 5′-GGG CTG CAA CAT TCG CAC AC-3′ and
5′-CCT CTC TCA GGA ACC AGG CAG-3′ for sPLA2-V, giving
PCR products with a length of 278 bp, 5′-CCA TCG CCT ATA
TGA AAT ATG G-3′ and 5′-TAG GAA CTG GGG GTA GAA
GAG-3′ for sPLA2-X, giving PCR products with a length of 295 bp,
and 5′-CGG AGT CAA CGG ATT TGG TCG TAT TG-3′ and
5′-GCA GGA GGC ATT GCT GAT GAT CTT G-3′ for GAPDH
amplifying products with a length of 439 bp. The oligonucleotides
for the analysis of mRNA were synthesized according to the published
nucleotide sequences of human sPLA2-IIA, sPLA2-V, sPLA2-X, and
GAPDH genes [21,29,30]. In the PCR, primer pairs were applied to
a final concentration of 0.8 μM. The conditions for amplification were
as follows: 40 cycles at 94°C for 30 seconds, 68°C for 30 seconds,
and 72°C for 1 minute. The buffers and reagents used were from
GeneAmp Kit (PerkinElmer LAS GmbH). After amplification, prod-
ucts were analyzed by electrophoresis on agarose gels. GAPDH mRNA
was determined in every sample as a reference.
Enzyme-Linked Immunosorbent Assays Specific for sPLA2-IIA
and Transcription Factors
The sPLA2-IIA protein released into the medium was determined
using an enzyme-linked immunosorbent assay (ELISA) kit according
to the manufacturer’s instructions (Cayman Chemical, MI). Culture
medium was removed, the cell surface–bound sPLA2-IIA was ex-
tracted with ice-cold PBS, pH 7.4, containing 1 M NaCl, and the ex-
tract was collected with cell culture medium, centrifuged for 10 minutes
at 400g to remove cell debris, and was used for sPLA2-IIA protein
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determination in the ELISA. Total cell protein was determined using a
Bicinchoninic Acid assay kit (Sigma-Aldrich).
For the determination of NF-κB, CAAT-enhancer–binding protein-
β (C/EBP-β), specificity protein 1 (SP1), and STAT1 DNA binding ac-
tivities, cells were incubated in six-well plates. After incubation, nuclear
extracts were prepared using a nuclear extraction kit (Active Motif,
Carlsbad, CA). The DNA binding capacities of NF-κB p65 and C/
EBP-β in nuclear extracts were estimated using ELISA-based assays
(Active Motif ) according to the manufacturer’s instructions. STAT1
and SP1 DNA binding activities were studied using STAT1 and SP1
ELISA kits from Panomics, Inc. (Fremont, CA). The phosphorylation
of STAT1 was measured using a cell-based ELISA kit (RayBiotech,
Inc., Norcross, GA) according to the manufacturer’s instructions.
DNA Sequencing
DNA sequences were analyzed with a genetic analyzer (ABI
PRISM 310; Perkin-Elmer Applied Biosystems, Foster City, CA).
Data Analysis
Data were analyzed by two-tailed and unpaired Student’s t test to
calculate the indicated P values. Differences were considered signifi-
cant at P < .05.
Results
Basal and Cytokine-Induced Expression of Group IIA, V, and
X Phospholipases A2 in Normal and Malignant Prostate Cells
In prostate cancer cells, PC-3 and LNCaP, sPLA2-IIA mRNA was
constitutively expressed, whereas in normal PrEC and malignant DU-
145 cells, no sPLA2-IIA transcripts were detectable (Figure 1). How-
ever, exposure to IFN-γ led to the induction of sPLA2-IIA expression
in PrEC and to further upregulation in PC-3 cells. No cytokine-
mediated induction of sPLA2-IIA transcripts occurred in DU-145 cells.
Similar results were also obtained at the protein level where negligible
amounts of sPLA2-IIA were released from DU-145 cells after incuba-
tion with cytokines (Figure 2). In LNCaP cells, sPLA2-IIA protein was
produced under normal conditions at about 700-fold higher levels
compared to PC-3 cells (Figure 2, A and B). This high basal expression
in LNCaP cells was further increased by IL-1β, TNF-α, and IL-6 treat-
ments by 5.0-, 2.0-, and 1.5-fold, respectively, but not by IFN-γ.
Transcripts of sPLA2-V were consistently detected in PC-3 and
LNCaP cells, but levels were relatively insensitive to the addition
of cytokines (Figure 1). In PrEC cells, no sPLA2-V transcripts were
detected, and these could not have been induced by any of the in-
vestigated cytokines. Under basal conditions, moderate levels of
sPLA2-V mRNA were detected in DU-145 cells; these levels were
strongly induced by IFN-γ. No inductive effects on sPLA2-V expres-
sion were observed in this cell line with IL-1β, IL-6, and TNF-α
(Figure 1). The sPLA2-X isozyme was strongly expressed in all stud-
ied cell lines, and no marked response to the added cytokines was
observed. In all samples, levels of GAPDH mRNA were comparable
(Figure 1).
Analysis of the active concentration range for IFN-γ indicated that
IFN-γ–mediated upregulation of sPLA2-IIA in normal PrEC and malig-
nant PC–3 cells was dose-dependent (Figure 2C ). A half-maximal effect
was observed at ∼4 ng/ml IFN-γ in PC-3 cells and at ∼12 ng/ml IFN-γ
in PrEC cells.
Regulation of sPLA2-IIA Expression by the Activity of
Signaling Pathways
Because, in DU-145 cells, no basal or cytokine-induced sPLA2-IIA
expressions were identifiable, we analyzed signaling components
only in PrEC, PC-3, and LNCaP cells. A marked increase in release
of sPLA2-IIA protein was observed in PrEC and PC-3 cells when
these cells were simultaneously stimulated with both IFN-γ and
forskolin, in comparison to cells exposed to IFN-γ alone (Figure 3).
In contrast, forskolin attenuated the sPLA2-IIA expression induced
by IL-1β in LNCaP cells. Phorbol-12-myristate 13-acetate, an acti-
vator of protein kinase C (PKC), inhibited the cytokine-stimulated
expression of sPLA2-IIA in all three analyzed cell types. H-1152, an
inhibitor of Rho-kinase, and PD-98059, an inhibitor of mitogen-
activated/extracellular response protein kinase, increased further the
cytokine-induced sPLA2-IIA production in PrEC, PC-3, and LNCaP
cells. Conversely, a significant suppression of sPLA2-IIA occurred in
prostate cell lines after exposure to SB-202190, mithramycin A, JAK
inhibitor-1, and CAPE, which inhibit p38 mitogen-activated protein
kinase (MAPK), SP1 binding activity, the JAK/STAT pathway, and
NF-κB, respectively. Other NF-κB inhibitors, such as pyrrolidine
dithiocarbamate, N-acetyl-L-cysteine, and 20S proteasome inhibitor,
also decreased the amounts of sPLA2-IIA released into the medium
(data not shown).
Figure 1. Agarose gel electrophoresis showing amplifiers of different secretory phospholipase A2 isozymes (sPLA2-IIA, sPLA2-V, and
sPLA2-X) and GAPDH mRNA after RT-PCR analysis expressed in normal and malignant prostate cell lines under basal conditions and
after exposure to proinflammatory cytokines. Cells were incubated for 24 hours in medium containing 10% FCS alone and additions of
cytokines at a final concentration of 25 ng/ml. Lanes 1 to 5 are controls (without additions of cytokines), IFN-γ, IL-1β, IL-6, and TNF-α,
respectively. Data are representative of at least three independent experiments giving similar results. AD and TP indicate the androgen
dependence and tumorigenicity potential according to literature [32,34].
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Activities of Transcription Factors in IFN-γ–Treated
Prostate Cells
Using a cell-based ELISA, we showed a marked difference in the
time course of cellular STAT1 phosphorylation (P-STAT1) induced
by IFN-γ (Figure 4). After 15 minutes of incubation, the highest
reactivity in P-STAT1 values was found in PC-3 cells followed by
PrEC and DU-145 cells. No increased P-STAT1 signals were de-
tected during the whole incubation time-course in LNCaP cells (Fig-
ure 4). In addition to STAT1 phosphorylation, we studied the DNA
binding activities of STAT1 using nuclear extracts of cells treated with
IFN-γ (Figure 5). There was a ∼20-fold activation of STAT1 in PC-3
cells after exposing to IFN-γ for 2 hours. In PrEC cells, this activation
averaged ∼10-fold, and in DU-145 cells, it averaged ∼ 6-fold. In
LNCaP cells, again no significant activation of STAT1 occurred.
Large differences were found in the basal binding activities of
STAT1, NF-κB, C/EBP-β, and SP1 between the different prostate
cell lines (Figure 5). In contrast to STAT1 activation, however, no
significant changes in DNA binding activities of NF-κB, C/EBP-β,
and SP1 were found, with the exception of SP1, the binding activity
of which decreased in PC-3 cells after incubation with IFN-γ (Fig-
ure 5). In LNCaP cells, treatment with IL-1β did not result in
STAT1 activation (data not shown).
Reexpression of sPLA2-IIA in DU-145 Cells After Treatment
with a DNA Methyltransferase Inhibitor
DU-145 cells do not express sPLA2-IIA either constitutively or
after exposure to cytokines. Therefore, we addressed the question
of whether failure of sPLA2-IIA expression in this cell line may be
due to PLA2G2A gene mutations. For this reason, we analyzed the
sequence of the proximal part of the promoter region [−319, +111]
and exons 2 to 5 of the PLA2G2A gene (access codes M22431 and
AY462114, transcription start site according to the study of Andreani
et al. [31]). Our data did not show substantial differences between
DU-145 DNA probes and the wild-type sequence (data not shown).
To define the contribution of epigenetic mechanisms, malignant
DU-145 cells were incubated with the DNA methyltransferase in-
hibitor, 5-aza-dC, for 48 to 96 hours. No transcripts specific for
sPLA2-IIA were present in DU-145 cells treated with DMSO as
a control, but transcripts became detectable after incubating with
Figure 2. Effects of proinflammatory cytokines on sPLA2-IIA ex-
pression in normal (PrEC) and malignant (DU-145, PC-3, and
LNCaP) prostate cells. Cytokines were added in a final concentra-
tion of 25 ng/ml. The sPLA2-IIA amounts released into the medium
by PrEC, PC-3, and DU-145 cells (A) were measured after 48 hours
of incubation. LNCaP cells (B) were incubated for 24 hours. *P <
.05 versus cells incubated without cytokines (basal expression). (C)
Concentration dependence of IFN-γ on sPLA2-IIA upregulation in
prostate cells. The results are expressed as changes relative to
the basal level of sPLA2-IIA secretion without IFN-γ treatment.
The basal levels of sPLA2-IIA (pg/mg cell protein) in PrEC, PC-3,
DU-145, and LNCaP cells were 10.05 ± 1.34; 13.11 ± 0.95;
2.50 ± 2.91, and 9898.15 ± 171.43, respectively. The prostate cells
were incubated with indicated concentrations of IFN-γ for 48 hours.
Results are the means ± SD of analysis in quadruplicate and are
representative of three independent experiments.
Figure 3. Effects of activators and inhibitors of cell signaling path-
ways on the sPLA2-IIA expression in normal PrEC and malignant
PC-3 cells stimulated with IFN-γ and in malignant LNCaP cells
stimulated with IL-1β. Cells were incubated for 48 hours. The
sPLA2-IIA levels (pg/mg cell protein) induced by corresponding cyto-
kines were 19.57 ± 2.96; 268.49 ± 4.61; 23640.0 ± 130.0 in PrEC,
PC-3, and LNCaP cells, respectively. Forskolin (Forsk; 10 μM), PMA
(30 ng/ml), H-1152 (10 μM), PD98059 (PD98; 50 μM), SB-202190
(SB202; 50 μM), mithramycin A (Mithra; 250 nM), CAPE (25 μM),
or JAK inhibitor-I (JAK Inh; 1 μM) was added simultaneously with
cytokines. Results are expressed as changes relative to the control
(treated just with cytokine) that was assigned a value of 1.0. The data
shown are the means ± SD of analysis in triplicate and are represen-
tative of four independent experiments.
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5-aza-dC (Figure 6A). The recovery of sPLA2-IIA expression after 48
to 96 hours of treatment with the DNA-demethylating agent was
confirmed by measuring the sPLA2-IIA protein released into the cell
culture medium (Figure 6B).
Discussion
In the current study, we present data on the expression of three
sPLA2 isoforms (IIA, V, and X) in normal human prostate cells
and in three cancer cell lines, PC-3, DU-145, and LNCaP, with dif-
fering tumorigenicity [32–34]. The results show that the sPLA2 iso-
zymes are differentially expressed and induced in different manners
in prostate cells. In normal PrEC prostate cells no basal expression of
sPLA2-IIA and sPLA2-V was detectable, whereas both isozymes were
constitutively expressed in malignant LNCaP and PC-3 cell lines.
Expression of sPLA2-IIA, but not the expression of sPLA2-V, was
inducible by IFN-γ in PC-3 and PrEC cells. Here, the IFN-γ–
mediated increase of sPLA2-IIA expression correlated strongly with
STAT1 activation.
In contrast to PC-3 and PrEC cells, in LNCaP cells, the expression
of sPLA2-IIA was completely insensitive to IFN-γ. This unrespon-
siveness agrees with the observation that LNCaP cells are unable to ini-
tiate IFN-γ signaling due to the lack of JAK1 expression caused by an
epigenetic mechanism [35]. For this reason, it was impossible to find a
significant STAT1 activation by IFN-γ in LNCaP cells. Nevertheless,
IL-1β, TNF-α, and IL-6 increased sPLA2-IIA expression in this cell
line. In PC-3 and PrEC cells, synthesis of sPLA2-IIA was completely
unresponsive to IL-1β, TNF-α, and IL-6, implying that corresponding
signaling events and transcription factors are not functionally active
in these cell lines. The finding that the JAK inhibitor-I, which sup-
presses both JAK1 and JAK2, significantly decreased sPLA2-IIA expres-
sion in LNCaP cells, although these cells do not possess JAK1 activity,
suggests that in addition to JAK1, a JAK2-dependent signaling pathway
is involved in the regulation of sPLA2-IIA.
Besides STAT1, other transcription factors, such as NF-κB, SP1,
and C/EBP-β, also exhibit specific binding sites in the sPLA2-IIA pro-
moter region [31,36]. Although the IFN-γ–mediated upregulation of
sPLA2-IIA in PrEC and PC-3 cells did not correlate with the activation
of NF-κB, SP1, and C/EBP-β, for an optimal expression of sPLA2-
IIA, at least NF-κB and SP1 are absolutely necessary. This conclusion
is based on a nearly complete inhibition of sPLA2-IIA by mithramycin
A, an inhibitor of SP1, and CAPE, an inhibitor of NF-κB, in PrEC,
PC-3, and LNCaP cells. In the case of C/EBP-β, no specific inhibitors
were available. Nevertheless, with the exception of DU-145 cells, the
basal DNA binding activities of C/EBP-β correlated strongly with the
sPLA2-IIA expression in prostate cells. This underlines that C/EBP-β
is also important for an optimal sPLA2-IIA expression.
In DU-145 cells, genomic analysis showed that both the failure of
basal sPLA2-IIA expression (see also Sved et al. [6]) and the distinct
lack of all tested cytokines to induce sPLA2-IIA expression at mRNA
and protein levels could not be explained by deletions in the sPLA2-
IIA gene. Our experiment on exposure of DU-145 cells to an inhib-
itor of methyltransferases (5-aza-dC) indicated, for the first time, that
the involvement of epigenetic mechanisms in the regulation of in
sPLA2-IIA expression. In cancer cells, epigenetic silencing of different
genes is caused by the aberrant methylation of cytosines belonging to
CpG islands, stretches of DNA rich in CpG dinucleotides often as-
sociated with gene promoters [19,37–41]. This methylation may
perturb the expression of genes critical to the regulation of cell pro-
liferation. In this context, one possible explanation for the activation
of the sPLA2-IIA in 5-aza-dC–treated DU-145 cells was that this
gene promoter contains CpG islands and that methylation of these
may be responsible for sPLA2-IIA gene silencing. However, analysis
of the PLA2G2A gene promoter region (−1000 to +200 bp from the
transcription start site according to the study of Andreani et al. [31])
performed using the EMBOSS-CpGPlot program (EMBL-European
Bioinformatics Institute; http://www.ebi.ac.uk) reveals no CpG is-
lands and a relatively low number of CpG sites. Nevertheless, it has
been shown that the presence of a single methylated CpG dinucleotide
within the binding sites of crucial transcription factors can be sufficient
for gene inactivation as described, for example, in the case of the SP1
binding site in the thymidine kinase gene [42]. Therefore, this mech-
anism may also be responsible for sPLA2-IIA gene silencing even when
no CpG islands are present in the promoter region. In agreement with
this suggestion, our results show that blockage of SP1 binding sites by
mithramycin A treatment almost completely abolished the expression
of sPLA2-IIA in PrEC, PC-3, and LNCaP cells (Figure 3).
Additional investigations have to clarify whether an aberrant meth-
ylation in DU-145 cells is taking place directly at selected CpG sites
within PLA2G2A promoter itself or indirectly through CpG meth-
ylation in the promoter of corresponding transcription factors that
regulate sPLA2-IIA transcription. The failed effect of DNA methyl-
transferase inhibition on sPLA2-IIA expression in rat mesangial cells
stimulated with cytokine IL-1β [43] suggests that perhaps such a
mechanism is absent in cells that normally express sPLA2-IIA.
A number of upstream pathways in both normal and malignant
prostate cells are involved in the activation of STAT1, NF-κB, C/
EBP-β, and SP1 transcription factors, with subsequent capacity to
modulate sPLA2-IIA expression. According to our data, p38 MAPK
kinase activates the sPLA2-IIA expression, whereas PKC, RhoA/Rho-
kinase, and mitogen-activated/extracellular response protein kinase /
Figure 4. Signal transducer and activator of transcription-1 (STAT1)
phosphorylation induced by IFN-γ in PrEC, PC-3, DU-145, and
LNCaP cells. The STAT1 phosphorylation was determined by
cell-based ELISA technique. Each point represents the mean of
cellular STAT1 activation expressed as the ratio P-STAT1/STAT1
and measured after 0, 10, 30, and 360 minutes of incubation with
25 ng/ml IFN-γ or 25 ng/ml IL-1β. The results are the means ±
SD of analysis in triplicate and are representative of three indepen-
dent experiments.
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extracellular signal–regulated kinase 1/2 pathways possess negative
regulatory effects. It is known that PKC interferes with other signal-
ing pathways leading to an inhibition of sPLA2-IIA expression. This
may relate to the sPLA2-IIA downregulation found in mesangial cells
[44]. Both p38 MAPK and survival kinase Akt pathways play critical
roles as downstream effectors of PKC isozymes in prostate cancer
cells [45]. Activation of PKC promotes the dephosphorylation and
inhibition of the Akt pathway, which is constitutively activated in
tumor cells.
In our study, we found a strong modulating effect of cAMP/protein
kinase A pathway on sPLA2-IIA expression in prostate cells. Forskolin,
an activator of this signaling cascade, either facilitated the induction of
sPLA2-IIA expression by IFN-γ in PrEC and PC-3 cells or repressed
the induction of sPLA2-IIA expression by IL-1β in LNCaP cells. The
reason of this forskolin-mediated opposite action remains unknown.
What relevance does different expression patterns of sPLA2-IIA
and sPLA2-V in prostate cell lines have for tumorigenic potential?
PC-3 and DU-145 cells have been identified as highly aggressive,
whereas the LNCaP cell line has a low aggressive phenotype [32,33].
The metastatic potentials of these prostate cancer cell lines correlates
with the expression of proangiogenic genes [34]. Based on these prop-
erties, the expression profiles of sPLA2 isozymes suggest that the
sPLA2-IIA plays, if any, only a secondary role in tumorigenicity. DU-
145 cells expressed, instead of sPLA2-IIA, the sPLA2-V isozyme, partic-
ularly after the exposure of cells to IFN-γ. Therefore, it is conceivable
that sPLA2-V compensates for the lack of expression of sPLA2-IIA
in DU-145 cells and contributes to oncogenesis in this cell line. In this
context, it is noteworthy that sPLA2-V isozyme acts similarly to sPLA2-
IIA at both arachidonic acid release [46] and arachidonic acid–mediated
signaling transduction in sPLA2-IIA-negative cell types [47,48]. Further
studies are necessary to elucidate the contribution of various sPLA2 iso-
zymes to proliferation, migration, invasion, cell-to-cell interaction, and
other activities in prostate cancer cells.
In summary, our study has elucidated several novel aspects about
expression of sPLA2 isozymes in normal (PrEC) and malignant (DU-
145, PC-3, and LNCaP) human prostate cell lines: (1) sPLA2-IIA,
sPLA2-V, and sPLA2-X are expressed in both normal prostate cells
and malignant prostate cell lines, but in a differential manner; (2) ex-
pression of sPLA2-IIA and sPLA2-V, but not of sPLA2-X, is con-
trolled by proinflammatory cytokines in prostate cells, but different
cell signaling pathways are involved in the regulation of sPLA2-IIA;
(3) no significant expression of sPLA2-IIA was found in the DU-145
cell line, and epigenetic mechanisms seem to be responsible for the
silencing of sPLA2-IIA in this cell line. Additional investigations may
Figure 5. Effects of IFN-γ on cellular STAT1, NF-κB, SP1, and C/EBP-β activities in nuclear extract of normal (PrEC) and malignant pros-
tate cells (PC-3, DU-145, and LNCaP). In nuclear cell extracts, the STAT1, NF-κB, SP1, and C/EBP-β DNA binding activities were
measured after a 2-hour exposure of cells to 25 ng/ml IFN-γ. Obtained data for each transcription factor were normalized toward the
signal level obtained in PrEC cells and are shown as means ± SD of the analyses in triplicate and are representative of three indepen-
dent experiments.
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clarify whether an aberrant methylation in DU-145 cells is taking
place directly at the promoter of the sPLA2-IIA gene itself or indirectly
through CpG methylation in the promoter of corresponding transcrip-
tion factors that regulate the synthesis of sPLA2-IIA in these cells.
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